Table 1 Description of study population (n = 80)
Characteristics | Total |
|---|---|
Total, n | 80 |
Age, years | |
Mean | 51.3 |
Range | 26–80 |
95% CI | 48.6–54 |
Age group | |
20–39 | 17 (21.3) |
40–59 | 38 (47.5) |
≥ 60 | 25 (31.2) |
Primary tumour diameter, mm | |
Mean | 32.67 |
Range | 10–70 |
95% CI | 29.51–35.84 |
T prior to NAC, n (%) | |
cT1 | 10 (12.5) |
cT2 | 52 (65) |
cT3 | 12 (15) |
cT4 | 6 (7.5) |
N prior to NAC, n (%) | |
cN0 | 39 (48.8) |
cN1 | 26 (32.5) |
cN2 | 6 (7.5) |
cN3 | 9 (11.2) |
T after surgery, n (%) | |
ypT0 | 27 (33.7) |
ypT1 | 28 (35) |
ypT2 | 19 (23.7) |
ypT3 | 5 (6.3) |
ypT4 | 1 (1.3) |
N after surgery, n (%) | |
ypN0 | 58 (72.5) |
ypN1 | 17 (21.2) |
ypN2 | 3 (3.8) |
ypN3 | 2 (2.5) |
NAC regimen, n (%) | |
Platinum containing | 47 (58.7) |
Nonplatinum containing | 33 (41.3) |
Germline BRCA1/2, n (%) | |
BRCA1 pathogenic variant | 25 (31.2) |
BRCA1 c.5117G > A | 6 |
BRCA1 c.5266dupC | 11 |
BRCA1 c.4035delA | 5 |
BRCA1 c.4675G > A | 1 |
BRCA1 c.843_846del | 1 |
BRCA1 c.181 T > G | 1 |
BRCA2 pathogenic variant | 1 (1.3) |
BRCA2 c.1813dupA | 1 |
BRCA1/2 wild type or unknown | 54 (67.5) |
Ki67, absolute count | |
Mean | 47.3 |
Range | 5–90 |
95% CI | 42.6–52.0 |
Ki67, n (%) | |
Low (< 50%) | 40 (50) |
High (≥ 50%) | 40 (50) |
Pathological response (Miller-Payne), n (%) | |
I-II | 19 (23.8) |
III-IV | 35 (43.7) |
V (pCR) | 26 (32.5) |
Surgery, n (%) | |
Sectoral resection + sentinel node biopsy | 35 (43.8) |
Sectoral resection + lymph node excision | 6 (7.5) |
Mastectomy + sentinel node biopsy | 14 (17.5) |
Mastectomy + lymph node excision | 11 (13.7) |
Bilateral mastectomy | 14 (17.5) |
Recurrence, n (%) | |
Present | 15 (18.7) |
Absent | 65 (81.3) |
Death, n (%) | |
Dead | 9 (11.2) |
Alive | 71 (88.8) |